🔓 Everything Pass · unlock every paragraph + the whole catalog for $29Get the Pass →
11-alzheimers-research-notes-discovery
This is the technical specification. The deliverable it describes is the full 11-alzheimers-research-notes-discovery blueprint package.
Enterprise blueprint packages settle by wire transfer — their value is above any card ceiling. Request the package below and a reference number is emailed to you straight away. The package ships to you on a Blu-ray disc once the wire clears, so include the address it should be mailed to.
Prefer the store page? Open the full product page.
Read the whole thing. Unlock all 21 locked sections of this description in one purchase.
Buy the whole description for $39.90Inventor: Christopher Gabriel Brown
U.S. Patent Application No.: 19/441,975, filed December 1, 2025 — pending examination at the USPTO
Title of Invention: Novel Metal–Amino Acid Complexes and Methods for Treating Alzheimer’s Disease
Discovery System: Alchemy Data V2 (elemental probability engine with pharmaceutical database cross‑referencing)
Original Discovery Date: January 11, 2026
Evidence Verification Date: February 23, 2026 (V2 peer‑review aligned); March 2026 (V3 scientifically corrected)
Research Status: Computational research findings — not clinically validated treatments
Patent Claims: 20 total (4 independent, 16 dependent) covering compositions, pharmaceutical formulations, methods of treatment, methods of synthesis, and use claims
Patent Drawings: 4 figures (chemical structures, synthesis scheme, coordination structures, pharmaceutical formulations)
Licence: Proprietary & Confidential — © 2026 Christopher Gabriel Brown. All rights reserved.
U.S. Patent Application No.: 19/441,975, filed December 1, 2025 — pending examination at the USPTO
Title of Invention: Novel Metal–Amino Acid Complexes and Methods for Treating Alzheimer’s Disease
Discovery System: Alchemy Data V2 (elemental probability engine with pharmaceutical database cross‑referencing)
Original Discovery Date: January 11, 2026
Evidence Verification Date: February 23, 2026 (V2 peer‑review aligned); March 2026 (V3 scientifically corrected)
Research Status: Computational research findings — not clinically validated treatments
Patent Claims: 20 total (4 independent, 16 dependent) covering compositions, pharmaceutical formulations, methods of treatment, methods of synthesis, and use claims
Patent Drawings: 4 figures (chemical structures, synthesis scheme, coordination structures, pharmaceutical formulations)
Licence: Proprietary & Confidential — © 2026 Christopher Gabriel Brown. All rights reserved.
This package documents a comprehensive body of computational research produced by the Alchemy Data V2 system. The system searches elemental combinations against pharmaceutical databases and drug‑reference indices, maps those elements to known biological mechanisms of Alzheimer’s disease, calculates discovery scores based on mechanism coverage and synthesis feasibility, and cross‑references findings against published peer‑reviewed scientific literature.
Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia, affecting over 55 million people worldwide (over 6 million in the United States alone, projected to reach 13 million by 2050). The global Alzheimer’s treatment market exceeds US $7 billion annually. Current treatments — cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine), and anti‑amyloid antibodies (lecanemab, donanemab) — provide only symptomatic relief or modest slowing of disease progression. No cure exists.
Read section 3 for $1.90The Alchemy Data V2 system identified 14 research compound candidates whose elemental compositions overlap with known Alzheimer’s disease mechanisms. The system correctly mapped the exact set of metals (Cu, Fe, Zn) and elemental signatures that 30+ years of peer‑reviewed research has confirmed are central to Alzheimer’s pathobiology. Every metal the system flagged IS involved in Alzheimer’s disease, validated by independent academic research spanning three decades.
Read section 4 for $1.90A critical finding of the peer‑review verification process: Alzheimer’s disease involves metal dyshomeostasis — not simple deficiency or excess. Copper, iron, and zinc accumulate at pathological concentrations in amyloid plaques (up to 0.5–1 mmol/L) while becoming simultaneously depleted from functional neuronal pools (synapses, enzymes). The therapeutic direction indicated by the evidence is redistribution and functional support, not supplementation of pathologically accumulating metals.
Read section 5 for $1.90The research targets the following Alzheimer’s disease pathology areas:
Read section 6 for $1.90Research statistics: 16 element combinations tested; 14 research candidates identified; top score 50.5/100 (C‑H‑O‑N); average probability 0.002569; 10 transformation methods available per compound; 1 synthesis method documented per compound.
Read section 7 for $1.90The patent application (19/441,975) discloses the following preferred embodiments, each with full mechanism coverage and synthesis specifications:
Read section 8 for $1.90The patent application provides detailed synthesis protocols for producing the metal‑amino acid coordination complexes. Three specific examples are documented:
Read section 9 for $1.90The package includes three progressive evidence reports (V1, V2, V3), with V2 correcting critical scientific errors from V1 and V3 adding specific sample sizes, p‑values, and the latest clinical trial data. Key evidence‑graded findings:
Read section 10 for $1.90The package includes a thorough analysis of why metal‑targeting drugs have failed in Alzheimer’s clinical trials, providing critical context for evaluating these research findings:
Read section 11 for $1.90Claim 17 of the patent application covers administration of the novel compounds in combination with existing approved Alzheimer’s medications:
Read section 12 for $1.90Based on the corrected evidence across all three report versions, the strongest therapeutic directions identified by the Alchemy discoveries are:
Read section 13 for $1.90The package includes comprehensive safety documentation covering known risks specific to Alzheimer’s patients:
Read section 14 for $1.90The evidence reports cite the following foundational studies (among others):
Read section 15 for $1.90The patent application specifies the following amino acids for coordination with the disclosed metal complexes:
Read section 16 for $1.90Specific amino acid selections for enhanced activity include: histidine for zinc (enhanced amyloid binding, Claim 5) and copper (enhanced amyloid clearance, Claim 6); cysteine or methionine for iron‑sulfur cluster formation (Claim 7); glycine or glutamic acid for enhanced mineral coordination (Claim 8).
Read section 17 for $1.90The research documentation clearly states that these are early‑stage computational findings requiring the following development pathway:
Read section 18 for $1.90The complete deliverable package includes every file in the
Read section 19 for $1.9011‑alzheimers‑cure‑discovery/ source tree and its sub‑directories:Important disclaimer: These are COMPUTATIONAL RESEARCH FINDINGS, not validated treatments. The compounds have NOT been synthesised for medical use, NOT tested in humans, NOT approved by any regulatory agency, and are NOT proven to treat or cure Alzheimer’s disease. This is early‑stage computational research requiring significant development work. Do NOT self‑treat any medical condition based on this research.
Read section 20 for $1.90This package ships on a single Blu-ray disc, posted to the delivery address on your order. The archive on the disc is AES-256 encrypted; the passphrase is sent separately, by email, once the disc is despatched — so the disc alone is of no use to anyone who intercepts it.
Read section 21 for $1.90Discs are despatched by tracked, signed-for post. Allow 5 business days for mastering and verification before despatch.
Read section 22 for $1.90© 2026 Christopher Gabriel Brown
Read section 23 for $1.90